Jean-Marc Treluyer

2025

Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase).

Human reproduction open ·doi:10.1093/hropen/hoae072

Study questionIs there an association between dydrogesterone exposure during early pregnancy and the reporting of birth defects?Summary answerThis observational analysis based on global safety data showed an increased reporting of birth def…

2025

Impact of clomiphene citrate on multiple gestation births and perinatal outcomes: a nationwide cohort study.

Fertility and sterility ·doi:10.1016/j.fertnstert.2025.04.005

ObjectiveTo evaluate the occurrence of multiple gestation birth and perinatal adverse outcomes in pregnancies resulting from clomiphene citrate (CC) treatment compared with nonexposed pregnancies.DesignNationwide cohort study in a universit…

other 2025

Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance

Human reproduction open ·doi:10.1093/hropen/hoaf031

2024

Trends over years and maternal characteristics associated with use of recommended drugs during pregnancy in France: a cross-sectional study

·doi:10.22541/au.173461330.02479899/v1

Aim: Pregnant women require different nutritional intake such as folic acid, iron and cholecalciferol, and specific vaccination to prevent fetal abnormalities and improve outcomes.. This study aims to analyze usage trends for these recomme…

2020

Comparing Dynamics and Determinants of SARS-CoV-2 Transmissions Among Health Care Workers of Adult and Paediatric Settings in Central Paris

SSRN Electronic Journal ·doi:10.2139/ssrn.3605174

Background: From the start of the pandemic, health-care workers (HCW) have paid a heavy toll to the coronavirus desease-19 (COVID-19) outbreak. Routes of transmission however remain to be fully understood. Methods: This prospective study c…